A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this class of drugs work better. The research is published in the journal Science Translational Medicine.
This article was originally published on MedicalXpress.com

